Lubiprostone
Generic Name: Lubiprostone
Brand Names: Amitiza
Lubiprostone activates chloride channels in the intestine to treat chronic constipation and IBS-C.
Drug Class
Chloride Channel Activator (ClC-2)
Pregnancy
Category C — Animal studies showed adverse fetal effects; use only if potential benefit justifies potential risk
Available Forms
8 mcg oral capsule, 24 mcg oral capsule
What It's Used For
Dosage Quick Reference
These are general dosage guidelines. Your doctor will determine the appropriate dose for your specific situation.
| Condition | Starting Dose | Typical Maintenance Dose |
|---|---|---|
| Chronic idiopathic constipation (adults) | 24 mcg twice daily with food | 24 mcg twice daily |
| Irritable bowel syndrome with constipation (IBS-C; women ≥18 years) | 8 mcg twice daily with food | 8 mcg twice daily |
| Opioid-induced constipation (adults with chronic non-cancer pain) | 24 mcg twice daily with food | 24 mcg twice daily |
Side Effects
Common Side Effects:
- Nausea (most common, up to 30%)
- Diarrhea
- Headache
- Abdominal pain or discomfort
- Abdominal distension
- Flatulence
Serious Side Effects:
- Severe diarrhea (discontinue if occurs)
- Dyspnea (shortness of breath, usually within an hour of first dose)
- Syncope (fainting)
- Hypotension
Drug Interactions
Major Drug & Food Interactions
- Methadone: May reduce lubiprostone efficacy; monitor bowel function closely in patients on methadone.
- Diphenylheptane opioids (e.g., methadone): Specific class of opioids that may decrease responsiveness to lubiprostone compared to other opioid classes.
- Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin): No significant pharmacokinetic interaction expected (lubiprostone is metabolized locally in the GI tract), but clinical caution is advised.
- Other laxatives or stool softeners: Combining with additional laxatives may increase diarrhea risk and electrolyte imbalances; use together with caution.
Additional Information
Lubiprostone is a locally acting chloride channel activator used to treat chronic idiopathic constipation (CIC), irritable bowel syndrome with constipation (IBS-C), and opioid-induced constipation (OIC). As the first FDA-approved medication in its class, lubiprostone represents an important therapeutic option for patients with difficult-to-treat constipation syndromes.
Mechanism of Action
Lubiprostone activates ClC-2 chloride channels on the apical (luminal) membrane of intestinal epithelial cells. This activation increases chloride-rich fluid secretion into the intestinal lumen without altering serum sodium or potassium concentrations. The increased intestinal fluid softens stool, accelerates intestinal transit time, and facilitates spontaneous bowel movements. Unlike stimulant laxatives, lubiprostone works through a specific molecular target and does not cause electrolyte imbalances or dependence.
Available Formulations
Lubiprostone is available as soft gelatin capsules:
- 8 mcg capsules: For IBS-C
- 24 mcg capsules: For CIC and OIC
The medication should be taken with food and water to minimize nausea, the most common side effect.
Medical Uses
FDA-Approved Indications:
- Chronic idiopathic constipation in adults
- Irritable bowel syndrome with constipation in women 18 years and older
- Opioid-induced constipation in adults with chronic non-cancer pain
The medication provides relief typically within 24-48 hours for many patients, with sustained benefit during continued therapy.
Dosing Guidelines
- CIC: 24 mcg twice daily with food and water
- IBS-C: 8 mcg twice daily with food and water
- OIC: 24 mcg twice daily with food and water
Dose reduction to 24 mcg once daily may be considered for patients with nausea. For patients with severe hepatic impairment (Child-Pugh Class C), starting doses should be reduced.
Important Safety Information
Contraindications:
- Known or suspected mechanical gastrointestinal obstruction
- Hypersensitivity to lubiprostone
Warnings and Precautions:
- Patients should be assessed for mechanical obstruction prior to initiating therapy
- Caution in patients with severe diarrhea
- Should not be prescribed for patients known to be pregnant (limited data)
- Nausea may be reduced by taking with food
Pregnancy Considerations: Lubiprostone is not recommended during pregnancy. Women of childbearing potential should have a negative pregnancy test before starting therapy and use effective contraception.
Drug Interactions
Lubiprostone has minimal systemic absorption, resulting in few drug interactions:
- Methadone: May reduce effectiveness of lubiprostone; higher doses may be needed
- Diphenylheptane opioids: May reduce lubiprostone efficacy
Special Populations
- Hepatic Impairment: Dose adjustment needed for moderate to severe impairment
- Renal Impairment: No dose adjustment required
- Elderly: No dose adjustment necessary; use with caution
- Pediatric: Safety and efficacy not established in children
Frequently Asked Questions
Questions to Ask Your Doctor
Consider discussing these topics at your next appointment:
- ✓Is lubiprostone a better choice for me compared to over-the-counter laxatives I have been using?
- ✓Could my current medications, especially opioids, be contributing to my constipation?
- ✓How long should I try lubiprostone before we evaluate whether it is working?
- ✓Are there dietary changes I should make alongside taking lubiprostone?
Related Health Conditions
This medication is commonly used to treat or manage the following conditions:
Medical Disclaimer: This information is for educational purposes only and should not be considered medical advice. Always consult with your healthcare provider before starting, stopping, or changing any medication. Your doctor can provide personalized recommendations based on your specific health condition and medical history.
Related Medications
Other medications in the same category
Questions About This Medication?
Talk to your doctor or pharmacist about whether Lubiprostone is right for you.
Contact UsCall: (727) 820-7800